SCHEMBL26685900

SCHEMBL26685900

Nc1n[nH]c2ccc(-c3ccnc(NC(=O)Nc4cccc(OCc5ccc(F)cc5)c4)c3)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F10 P00742 14/20 0.49
▸ KDR P35968 4/20 0.45
▸ F2 P00734 1/20 0.45
▸ ELANE P08246 1/20 0.45
▸ KIT P10721 3/20 0.44
▸ FLT3 P36888 3/20 0.44
▸ LCK P06239 2/20 0.43
▸ FYN P06241 2/20 0.43
▸ CSF1R P07333 2/20 0.43
▸ LYN P07948 2/20 0.43
▸ FLT1 P17948 2/20 0.43
▸ FLT4 P35916 2/20 0.43
▸ BLK P51451 2/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ SRC P12931 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ PLK4 O00444 1/20 0.43
▸ AURKA O14965 1/20 0.43
▸ ROCK2 O75116 1/20 0.43
▸ CHEK2 O96017 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633375 1.00 F10 (0.49) F10KDRF2ELANEKIT
SCHEMBL26685995 0.94 MAPK1 (0.49) F10KDRF2ELANEKIT
SCHEMBL30633282 0.94 MAPK1 (0.49) F10KDRF2ELANEKIT
SCHEMBL26686298 0.93 MEN1 (0.48) F10KDRKITFLT3MAPK1
SCHEMBL30633297 0.93 MEN1 (0.48) F10KDRKITFLT3MAPK1
SCHEMBL30633302 0.89 F10 (0.46) F10KDRF2KITFLT3
SCHEMBL26686210 0.89 F10 (0.46) F10KDRF2KITFLT3
SCHEMBL30633305 0.86 KDR (0.57) KDRKITFLT3LCKFYN
SCHEMBL26686045 0.86 KDR (0.57) KDRKITFLT3LCKFYN
SCHEMBL30633403 0.85 JAK2 (0.57) KDRKITFLT3LCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB F10 2348/4885KDR 2334/4885F2 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback